Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma

Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tiejun, Xue, Yuwen, Wang, Guilan, Gu, Tingting, Li, Yunlong, Zhu, York Yuanyuan, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934040/
https://www.ncbi.nlm.nih.gov/pubmed/27390607
http://dx.doi.org/10.7150/jca.15157
_version_ 1782441272777113600
author Li, Tiejun
Xue, Yuwen
Wang, Guilan
Gu, Tingting
Li, Yunlong
Zhu, York Yuanyuan
Chen, Li
author_facet Li, Tiejun
Xue, Yuwen
Wang, Guilan
Gu, Tingting
Li, Yunlong
Zhu, York Yuanyuan
Chen, Li
author_sort Li, Tiejun
collection PubMed
description Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 and VEGF, compared with single target siRNA. Moreover, multi-target siRNA showed greater suppression effects on proliferation, migration, invasion, angiogenesis and induced apoptosis in HCC cells. The results suggested that multi-target siRNA might be a preferred strategy for cancer therapy and NET-1, EMS1 and VEGF could be effective targets for HCC treatments.
format Online
Article
Text
id pubmed-4934040
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-49340402016-07-07 Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma Li, Tiejun Xue, Yuwen Wang, Guilan Gu, Tingting Li, Yunlong Zhu, York Yuanyuan Chen, Li J Cancer Research Paper Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 and VEGF, compared with single target siRNA. Moreover, multi-target siRNA showed greater suppression effects on proliferation, migration, invasion, angiogenesis and induced apoptosis in HCC cells. The results suggested that multi-target siRNA might be a preferred strategy for cancer therapy and NET-1, EMS1 and VEGF could be effective targets for HCC treatments. Ivyspring International Publisher 2016-06-25 /pmc/articles/PMC4934040/ /pubmed/27390607 http://dx.doi.org/10.7150/jca.15157 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Li, Tiejun
Xue, Yuwen
Wang, Guilan
Gu, Tingting
Li, Yunlong
Zhu, York Yuanyuan
Chen, Li
Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title_full Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title_fullStr Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title_full_unstemmed Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title_short Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
title_sort multi-target sirna: therapeutic strategy for hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934040/
https://www.ncbi.nlm.nih.gov/pubmed/27390607
http://dx.doi.org/10.7150/jca.15157
work_keys_str_mv AT litiejun multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT xueyuwen multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT wangguilan multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT gutingting multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT liyunlong multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT zhuyorkyuanyuan multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma
AT chenli multitargetsirnatherapeuticstrategyforhepatocellularcarcinoma

Ejemplares similares